An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of MK-2828 in Participants With Renal Impairment
Latest Information Update: 03 Mar 2026
At a glance
- Drugs MK 2828 (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Acronyms MK-2828-006
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 27 Feb 2026 Planned initiation date changed from 24 Feb 2026 to 2 Mar 2026.
- 27 Feb 2026 Status changed from not yet recruiting to recruiting.
- 27 Jan 2026 New trial record